Emerging roles of cysteine cathepsins in disease and their potential as drug targets

Current Pharmaceutical Design

Volumn 13, Issue 4, 2007, Pages 387-403

  Vasiljeva, Olga ^a,b   Reinheckel, Thomas ^a   Peters, Christoph ^a   Turk, Dušan ^b   Turk, Vito ^b   Turk, Boris ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Apoptosis; Cancer biology; Carboxypeptidases cathepsins B; Extracellular matrix (ECM); MHC class II antigen; Tumour angiogenesis

Indexed keywords

AFG 495; ANTIPAIN; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN; CATHEPSIN B; CATHEPSIN F; CATHEPSIN H; CATHEPSIN K; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S INHIBITOR; CRA 013783; CRA 028129; CYSTEINE; CYSTEINE PROTEINASE INHIBITOR; CYTOKINE; ENZYME INHIBITOR; GLYCOSAMINOGLYCAN; HORMONE PRECURSOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; JNJ 10329670; LEUPEPTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; MV 57471; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; RELACATIB; SB 357114; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ANTIGEN PRESENTATION; APOPTOSIS; ASTHMA; BONE NECROSIS; BONE REMODELING; CANCER INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; FEVER; FRACTURE NONUNION; GASTROINTESTINAL IRRITATION; HUMAN; IMMUNE DEFICIENCY; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; TISSUE DISTRIBUTION; VIRUS INFECTION; WOUND HEALING;

EID: 33947604810     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780162962     Document Type: Review

References (223)

1. Rossi A, Deveraux Q, Turk B, Šali A. Comprehensive search for cysteine cathepsins in the human genome. Biol Chem 2004; 385: 363-72.
2. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J 2001; 20: 4629-33.
3. Barrett AJ. Cellular proteolysis. An overview. Ann N Y Acad Sci 1992; 674: 1-15.
4. Pinitglang S, Watts AB, Patel M, Reid JD, Noble MA, Gul S, et al. A classical enzyme active center motif lacks catalytic competence until modulated electrostatically. Biochemistry 1997; 36: 9968-82.
5. Turk D, Gunčar G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr 2003; 59: 203-13.
6. Turk D, Gunčar G, Podobnik M, Turk B. Revised definition of substrate binding sites of papain-like cysteine proteases. Biol Chem 1998; 379: 137-47.
7. Musil D, Zučić D, Turk D, Engh RA, Mayr I, Huber R, et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J 1991; 10: 2321-30.
8. Gunčar G, Klemenčić I, Turk B, Turk V, Karaoglanovic-Carmona A, Juliano L, et al. Crystal structure of cathepsin X: a flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxydipeptidase activity of the protease. Structure 2000; 8: 305-13.
9. Nägler DK, Zhang R, Tam W, Sulea T, Purisima EO, Menard R. Human cathepsin X: A cysteine protease with unique carboxypeptidase activity. Biochemistry 1999; 38: 12648-54.
10. Gunčar G, Podobnik M, Pungerčar J, Štrukelj B, Turk V, Turk D. Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. Structure 1998; 6: 51-61.
11. Turk D, Janjić V, Stern I, Podobnik M, Lamba D, Dahl SW, et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J 2001; 20: 6570-82.
12. Olsen JG, Kadziola A, Lauritzen C, Pedersen J, Larsen S, Dahl SW. Tetrameric dipeptidyl peptidase I directs substrate specificity by use of the residual pro-part domain. FEBS Lett 2001; 506: 201-6.
13. Podobnik M, Kuhelj R, Turk V, Turk D. Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen. J Mol Biol 1997; 271: 774-88.
14. Cygler M, Sivaraman J, Grochulski P, Coulombe R, Storer AC, Mort JS. Structure of rat procathepsin B: model for inhibition of cysteine protease activity by the proregion. Structure 1996; 4: 405-16.
15. Coulombe R, Grochulski P, Sivaraman J, Menard R, Mort JS, Cygler M. Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. EMBO J 1996; 15: 5492-503.
16. LaLonde JM, Zhao B, Janson CA, D'Alessio KJ, McQueney MS, Orsini MJ, et al. The crystal structure of human procathepsin K. Biochemistry 1999; 38: 862-9.
17. Sivaraman J, Lalumiere M, Menard R, Cygler M. Crystal structure of wild-type human procathepsin K. Protein Sci 1999; 8: 283-90.
18. Turk D, Podobnik M, Kuhelj R, Dolinar M, Turk V. Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide. FEBS Lett 1996; 384: 211-4.
19. Rozman J, Stojan J, Kuhelj R, Turk V, Turk B. Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett 1999; 459: 358-62.
20. Vasiljeva O, Dolinar M, Rozman Pungercar J, Turk V, Turk B. Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans. FEBS Lett 2005; 579: 1285-90.
21. McQueney MS, Amegadzie BY, D'Alessio K, Hanning CR, McLaughlin MM, McNulty D, et al. Autocatalytic activation of human cathepsin K. J Biol Chem 1997; 272: 13955-60.
22. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 2000; 1477: 98-111.
23. Dahl SW, Halkier T, Lauritzen C, Dolenc I, Pedersen J, Turk V, et al. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing. Biochemistry 2001; 40: 1671-8.
24. Turk V, Turk B, Gunčar G, Turk D, Kos J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul 2002; 42: 285-303.
25. Turk B, Turk D, Salvesen G. Regulating cysteine protease activity: Essential role of protease inhibitors as guardians and regulators. Medicinal Chem Rev 2005: 283-97.
26. Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet 1998; 20: 251-8.
27. Almeida PC, Nantes IL, Chagas JR, Rizzi CC, Faljoni-Alario A, Carmona E, et al. Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation. J Biol Chem 2001; 276: 944-51.
28. Li Z, Hou WS, BrömmeD. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry 2000; 39: 529-36.
29. Li Z, Yasuda Y, Li W, Bogyo M, Katz N, Gordon RE, et al. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem 2004; 279: 5470-9.
30. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
31. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases) - on the main stage of cancer? Cancer Cell 2004; 5: 409-10.
32. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem 2004; 385: 1017-27.
33. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004; 5: 443-53.
34. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006; 20: 543-56.
35. Goulet B, Baruch A, Moon NS, Poirier M, Sansregret LL, Erickson A, et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell 2004; 14: 207-19.
36. Sokol JP, Schiemann WP. Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res 2004; 2: 183-95.
37. Roth W, Deussing J, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J 2000; 14: 2075-86.
38. Reinheckel T, Hagemann S, Dollwet-Mack S, Martinez E, Lohmuller T, Zlatkovic G, et al. The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J Cell Sci 2005; 118: 3387-95.
39. Kroemer G, Jäättelä M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005; 5: 886-97.
40. Zhao M, Antunes F, Eaton JW, Brunk UT. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem 2003; 270: 3778-86.
41. Roberts LR, Kurosawa H, Bronk SF, Fesmier PJ, Agellon LB, Leung WY, et al. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology 1997; 113: 1714-26.
42. Baskin-Bey ES, Canbay A, Bronk SF, Werneburg N, Guicciardi ME, Nyberg SL, et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2005; 288: G396-402.
43. Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FA, Giaccone G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 2004; 64: 27-30.
44. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000; 106: 1127-37.
45. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001; 153: 999-1010.
46. Taha TA, Kitatani K, Bielawski J, Cho W, Hannun YA, Obeid LM. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 2005; 280: 17196-202.
47. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, Boes M, et al. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 2004; 64: 5301-10.
48. Werneburg N, Guicciardi ME, Yin XM, Gores GJ. TNF-alphamediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. Am J Physiol Gastrointest Liver Physiol 2004; 287: G436-43.
49. Vancompernolle K, Van Herreweghe F, Pynaert G, Van de Craen M, De Vos K, Totty N, et al. Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity. FEBS Lett 1998; 438: 150-8.
50. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, et al. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem 2001; 276: 3149-57.
51. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-8.
52. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 1992; 282 (Pt 1): 273-8.
53. Mai J, Sameni M, Mikkelsen T, Sloane BF. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem 2002; 383: 1407-13.
54. Kruszewski WJ, Rzepko R, Wojtacki J, Skokowski J, Kopacz A, Jaskiewicz K, et al. Overexpression of cathepsin B correlates with angiogenesis in colon adenocarcinoma. Neoplasma 2004; 51: 38-43.
55. Yanamandra N, Gumidyala KV, Waldron KG, Gujrati M, Olivero WC, Dinh DH, et al. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 2004; 23: 2224-30.
56. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, et al. Cathepsin S controls angiogenesis and tumor growth via matrixderived angiogenic factors. J Biol Chem 2006; 281: 6020-9.
57. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 2003; 92: 493-500.
58. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3: 422-33.
59. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19: 1187-94.
60. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 486: 247-51.
61. Im E, Venkatakrishnan A, Kazlauskas A. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 2005; 16: 3488-500.
62. Jin H, Aiyer A, Su J, Borgstrom P, Stupack D, Friedlander M, et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest 2006; 116: 652-62.
63. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005; 11: 206-13.
64. Kjoller L, Engelholm LH, Hoyer-Hansen M, Dano K, Bugge TH, Behrendt N. uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Exp Cell Res 2004; 293: 106-16.
65. Sameni M, Moin K, Sloane BF. Imaging proteolysis by living human breast cancer cells. Neoplasia 2000; 2: 496-504.
66. Heidtmann HH, Salge U, Abrahamson M, Bencina M, Kastelic L, Kopitar-Jerala N, et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clin Exp Metastasis 1997; 15: 368-81.
67. Maciewicz RA, Wardale RJ, Etherington DJ, Paraskeva C. Immunodetection of cathepsins B and L present in and secreted from human pre-malignant and malignant colorectal tumour cell lines. Int J Cancer 1989; 43: 478-86.
68. Koblinski JE, Dosescu J, Sameni M, Moin K, Clark K, Sloane BF. Interaction of human breast fibroblasts with collagen I increases secretion of procathepsin B. J Biol Chem 2002; 277: 32220-7.
69. Frosch BA, Berquin I, Emmert-Buck MR, Moin K, Sloane BF. Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 1999; 107: 28-37.
70. Miyake H, Hara I, Eto H. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression. Anticancer Res 2004; 24: 2573-7.
71. Luthgens K, Ebert W, Trefz G, Gabrijelčič D, Turk V, Lah T. Cathepsin B and cysteine proteinase inhibitors in bronchoalveolar lavage fluid of lung cancer patients. Cancer Detect Prev 1993; 17: 387-97.
72. Nagai A, Terashima M, Harada T, Shimode K, Takeuchi H, Murakawa Y, et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chim Acta 2003; 329: 53-60.
73. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994; 54: 6517-25.
74. Linebaugh BE, Sameni M, Day NA, Sloane BF, Keppler D. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem 1999; 264: 100-9.
75. Cavallo-Medved D, Dosescu J, Linebaugh BE, Sameni M, Rudy D, Sloane BF. Mutant K-ras regulates cathepsin B localization in caveolae of human colorectal carcinoma cells. Neoplasia 2003; 5: 507-19.
76. Annabi B, Lachambre M, Bousquet-Gagnon N, Page M, Gingras D, Beliveau R. Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J 2001; 353: 547-53.
77. Stahl A, Mueller BM. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 1995; 129: 335-44.
78. Campo E, Munoz J, Miquel R, Palacin A, Cardesa A, Sloane BF, et al. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol 1994; 145: 301-9.
79. Marten K, Bremer C, Khazaie K, Sameni M, Sloane B, Tung CH, et al. Detection of dysplastic intestinal adenomas using enzymesensing molecular beacons in mice. Gastroenterology 2002; 122: 406-14.
80. Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 2006; 66: 5242-50.
81. Creemers LB, Hoeben KA, Jansen DC, Buttle DJ, Beertsen W, Everts V. Participation of intracellular cysteine proteinases, in particular cathepsin B, in degradation of collagen in periosteal tissue explants. Matrix Biol 1998; 16: 575-84.
82. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinasetype plasminogen activator (Pro-uPA). J Biol Chem 1991; 266: 5147-52.
83. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1993; 1178: 55-62.
84. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, et al. Mechanisms for pro matrix metalloproteinase activation. Apmis 1999; 107: 38-44.
85. van Kempen LC, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer 2006; 42: 728-34.
86. Fernandez PL, Farre X, Nadal A, Fernandez E, Peiro N, Sloane BF, et al. Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 2001; 95: 51-5.
87. McKerrow JH, Bhargava V, Hansell E, Huling S, Kuwahara T, Matley M, et al. A functional proteomics screen of proteases in colorectal carcinoma. Mol Med 2000; 6: 450-60.
88. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
89. Beers C, Honey K, Fink S, Forbush K, Rudensky A. Differential regulation of cathepsin S and cathepsin L in interferon gammatreated macrophages. J Exp Med 2003; 197: 169-79.
90. Katunuma N, Matsunaga Y, Matsui A, Kakegawa H, Endo K, Inubushi T, et al. Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption. Adv Enzyme Regul 1998; 38: 235-51.
91. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci USA 1998; 95: 4516-21.
92. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998; 280: 450-3.
93. Brömme D, Li Z, Barnes M, Mehler E. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry 1999; 38: 2377-85.
94. Tolosa E, Li W, Yasuda Y, Wienhold W, Denzin LK, Lautwein A, et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest 2003; 112: 517-26.
95. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999; 10: 207-17.
96. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-7.
97. Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999; 10: 197-206.
98. Driessen C, Bryant RA, Lennon-Dumenil AM, Villadangos JA, Bryant PW, Shi GP, et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J Cell Biol 1999; 147: 775-90.
99. Pierre P, Mellman I. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 1998; 93: 1135-45.
100. Shi GP, Bryant RA, Riese R, Verhelst S, Driessen C, Li Z, et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med 2000; 191: 1177-86.
101. Tang CH, Lee JW, Galvez MG, Robillard L, Mole SE, Chapman HA. Murine cathepsin f deficiency causes neuronal lipofuscinosis and late-onset neurological disease. Mol Cell Biol 2006; 26: 2309-16.
102. Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci USA 1999; 96: 8627-32.
103. Mabee CL, McGuire MJ, Thiele DL. Dipeptidyl peptidase I and granzyme A are coordinately expressed during CD8+ T cell development and differentiation. J Immunol 1998; 160: 5880-5.
104. Thiele DL, McGuire MJ, Lipsky PE. A selective inhibitor of dipeptidyl peptidase I impairs generation of CD8+ T cell cytotoxic effector function. J Immunol 1997; 158: 5200-10.
105. Pham CT, Ivanovich JL, Raptis SZ, Zehnbauer B, Ley TJ. Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J Immunol 2004; 173: 7277-81.
106. Brömme D, Kaleta J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr Pharm Des 2002; 8: 1639-58.
107. Cirman T, Orešoć K, Droga Mazovec G, Turk V, Reed JC, Myers RM, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem 2004; 279: 3578-87.
108. Baer GS, Dermody TS. Mutations in reovirus outer-capsid protein sigma3 selected during persistent infections of L cells confer resistance to protease inhibitor E64. J Virol 1997; 71: 4921-8.
109. Ebert DH, Wetzel JD, Brumbaugh DE, Chance SR, Stobie LE, Baer GS, et al. Adaptation of reovirus to growth in the presence of protease inhibitor E64 segregates with a mutation in the carboxy terminus of viral outer-capsid protein sigma3. J Virol 2001; 75: 3197-206.
110. Baer GS, Ebert DH, Chung CJ, Erickson AH, Dermody TS. Mutant cells selected during persistent reovirus infection do not express mature cathepsin L and do not support reovirus disassembly. J Virol 1999; 73: 9532-43.
111. Ebert DH, Deussing J, Peters C, Dermody TS. Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J Biol Chem 2002; 277: 24609-17.
112. Golden JW, Linke J, Schmechel S, Thoemke K, Schiff LA. Addition of exogenous protease facilitates reovirus infection in many restrictive cells. J Virol 2002; 76: 7430-43.
113. Golden JW, Bahe JA, Lucas WT, Nibert ML, Schiff LA. Cathepsin S supports acid-independent infection by some reoviruses. J Biol Chem 2004; 279: 8547-57.
114. Pager CT, Dutch RE. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J Virol 2005; 79: 12714-20.
115. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005; 308: 1643-5.
116. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 2005; 102: 11876-81.
117. Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, et al. SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells. J Biol Chem 2006; 281: 3198-203.
118. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA 2005; 102: 7988-93.
119. Teitelbaum SL. Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res Ther 2005; 8: 201.
120. Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R. Toward a molecular understanding of skeletal development. Cell 1995; 80: 371-8.
121. Delaisse JM, Eeckhout Y, Vaes G. Inhibition of bone resorption in culture by inhibitors of thiol proteinases. Biochem J 1980; 192: 365-8.
122. Delaisse JM, Boyde A, Maconnachie E, Ali NN, Sear CH, Eeckhout Y, et al. The effects of inhibitors of cysteine-proteinases and collagenase on the resorptive activity of isolated osteoclasts. Bone 1987; 8: 305-13.
123. Everts V, Beertsen W, Tigchelaar-Gutter W. The digestion of phagocytosed collagen is inhibited by the proteinase inhibitors leupeptin and E-64. Coll Relat Res 1985; 5: 315-36.
124. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995; 206: 89-96.
125. Littlewood-Evans A, Kokubo T, Ishibashi O, Inaoka T, Wlodarski B, Gallagher JA, et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 1997; 20: 81-6.
126. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998; 273: 32347-52.
127. Kafienah W, Brömme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J 1998; 331(Pt 3): 727-32.
128. Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 1997; 12: 1396-406.
129. Lazner F, Gowen M, Pavasovic D, Kola I. Osteopetrosis and osteoporosis: two sides of the same coin. Hum Mol Genet 1999; 8: 1839-46.
130. Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 2001; 16: 1444-52.
131. Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 2005; 36: 159-72.
132. Morko J, Kiviranta R, Hurme S, Rantakokko J, Vuorio E. Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K. Bone 2005; 36: 854-65.
133. Morko J, Kiviranta R, Joronen K, Saamanen AM, Vuorio E, Salminen-Mankonen H. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum 2005; 52: 3713-7.
134. Rantakokko J, Uusitalo H, Jamsa T, Tuukkanen J, Aro HT, Vuorio E. Expression profiles of mRNAs for osteoblast and osteoclast proteins as indicators of bone loss in mouse immobilization osteopenia model. J Bone Miner Res 1999; 14: 1934-42.
135. Kakudo S, Mano H, Shiokawa M, Mori Y, Kumegawa M, Hakeda Y. Concanavalin A directly stimulates bone-resorbing activity of osteoclasts and their gene expression of cathepsin K/OC-2. Biochem Biophys Res Commun 1997; 234: 600-4.
136. Holzer G, Noske H, Lang T, Holzer L, Willinger U. Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 2005; 146: 13-7.
137. Wang D, Li W, Pechar M, Kopeckova P, Brömme D, Kopecek J. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis. Int J Pharm 2004; 277: 73-9.
138. Deaton DN, Kumar S. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents. Prog Med Chem 2004; 42: 245-375.
139. Millest AJ, Breen SA, Loveday BE, Clarkson PN, Simpson CA, Waterton JC, et al. Effects of an inhibitor of cathepsin L on bone resorption in thyroparathyroidectomized and ovariectomized rats. Bone 1997; 20: 465-71.
140. Potts W, Bowyer J, Jones H, Tucker D, Freemont AJ, Millest A, et al. Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol 2004; 85: 85-96.
141. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273: 1236-8.
142. Motyckova G, Fisher DE. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med 2002; 2: 407-21.
143. Hou WS, Brömme D, Zhao Y, Mehler E, Dushey C, Weinstein H, et al. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest 1999; 103: 731-8.
144. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998; 95: 13453-8.
145. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999; 14: 1654-63.
146. Pisetsky DS, St Clair EW. Progress in the treatment of rheumatoid arthritis. Jama 2001; 286: 2787-90.
147. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999; 26: 717-9.
148. Lenarčič B, Gabrijelčič D, Rozman B, Drobnič-Košrok M, Turk V. Human cathepsin B and cysteine proteinase inhibitors (CPIs) in inflammatory and metabolic joint diseases. Biol Chem Hoppe Seyler 1988; 369 Suppl: 257-61.
149. Huet G, Flipo RM, Colin C, Janin A, Hemon B, Collyn-d'Hooghe M, et al. Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1993; 36: 772-80.
150. Esser RE, Angelo RA, Murphey MD, Watts LM, Thornburg LP, Palmer JT, et al. Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis. Arthritis Rheum 1994; 37: 236-47.
151. Hansen T, Petrow PK, Gaumann A, Keyszer GM, Eysel P, Eckardt A, et al. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium. J Rheumatol 2000; 27: 859-65.
152. Keyszer G, Redlich A, Haupl T, Zacher J, Sparmann M, Engethum U, et al. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Arthritis Rheum 1998; 41: 1378-87.
153. Lemaire R, Huet G, Zerimech F, Grard G, Fontaine C, Duquesnoy B, et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol 1997; 36: 735-43.
154. Etherington DJ, Taylor MA, Henderson B. Elevation of cathepsin L levels in the synovial lining of rabbits with antigen-induced arthritis. Br J Exp Pathol 1988; 69: 281-9.
155. Hill PA, Buttle DJ, Jones SJ, Boyde A, Murata M, Reynolds JJ, et al. Inhibition of bone resorption by selective inactivators of cysteine proteinases. J Cell Biochem 1994; 56: 118-30.
156. Schedel J, Seemayer CA, Pap T, Neidhart M, Kuchen S, Michel BA, et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther 2004; 11: 1040-7.
157. Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002; 109: 363-71.
158. Aznavoorian S, Moore BA, Alexander-Lister LD, Hallit SL, Windsor LJ, Engler JA. Membrane type I-matrix metalloproteinasemediated degradation of type I collagen by oral squamous cell carcinoma cells. Cancer Res 2001; 61: 6264-75.
159. Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003; 112: 152-9.
160. Reddy VY, Zhang QY, Weiss SJ. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acad Sci USA 1995; 92: 3849-53.
161. Biroc SL, Gay S, Hummel K, Magill C, Palmer JT, Spencer DR, et al. Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor. Arthritis Rheum 2001; 44: 703-11.
162. Brömme D, Okamoto K, Wang BB, Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996; 271: 2126-32.
163. Goldring SR. Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol Suppl 2002; 65: 44-8.
164. Bank U, Kruger S, Langner J, Roessner A. Review: peptidases and peptidase inhibitors in the pathogenesis of diseases. Disturbances in the ubiquitin-mediated proteolytic system. Protease-antiprotease imbalance in inflammatory reactions. Role of cathepsins in tumour progression. Adv Exp Med Biol 2000; 477: 349-78.
165. Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005; 57: 973-93.
166. Konttinen YT, Mandelin J, Li TF, Salo J, Lassus J, Liljestrom M, et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum 2002; 46: 953-60.
167. Kiyoshima T, Kido MA, Nishimura Y, Himeno M, Tsukuba T, Tashiro H, et al. Immunocytochemical localization of cathepsin L in the synovial lining cells of the rat temporomandibular joint. Arch Oral Biol 1994; 39: 1049-56.
168. Maciewicz RA, Wotton SF, Etherington DJ, Duance VC. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Lett 1990; 269: 189-93.
169. Baici A, Horler D, Lang A, Merlin C, Kissling R. Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage. Ann Rheum Dis 1995; 54: 281-8.
170. Mehraban F, Tindal MH, Proffitt MM, Moskowitz RW. Temporal pattern of cysteine endopeptidase (cathepsin B) expression in cartilage and synovium from rabbit knees with experimental osteoarthritis: gene expression in chondrocytes in response to interleukin-1 and matrix depletion. Ann Rheum Dis 1997; 56: 108-15.
171. Lai WF, Chang CH, Tang Y, Bronson R, Tung CH. Early diagnosis of osteoarthritis using cathepsin B sensitive near-infrared fluorescent probes. Osteoarthritis Cartilage 2004; 12: 239-44.
172. Berardi S, Lang A, Kostoulas G, Horler D, Vilei EM, Baici A. Alternative messenger RNA splicing and enzyme forms of cathepsin B in human osteoarthritic cartilage and cultured chondrocytes. Arthritis Rheum 2001; 44: 1819-31.
173. Morko JP, Soderstrom M, Saamanen AM, Salminen HJ, Vuorio EI. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 2004; 63: 649-55.
174. Pelletier JP, Boileau C, Brunet J, Boily M, Lajeunesse D, Reboul P, et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 2004; 34: 527-38.
175. Jovanovic DV, Fernandes JC, Martel-Pelletier J, Jolicoeur FC, Reboul P, Laufer S, et al. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis. Arthritis Rheum 2001; 44: 2320-30.
176. Grabowska U, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discov Devel 2005; 8: 619-30.
177. Premzl A, Zavašnik-Bergant V, Turk V, Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res 2003; 283: 206-14.
178. Marquis RW, Ru Y, LoCastro SM, Zeng J, Yamashita DS, Oh HJ, et al. Azepanone-based inhibitors of human and rat cathepsin K. J Med Chem 2001; 44: 1380-95.
179. Kung Sutherland MS, Lipps SG, Patnaik N, Gayo-Fung LM, Khammungkune S, Xie W, et al. SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF. Cytokine 2003; 23: 1-14.
180. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2004; 2: 6.
181. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2001; 16: 1739-46.
182. Barrett DG, Catalano JG, Deaton DN, Long ST, Miller LR, Tavares FX, et al. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett 2004; 14: 2543-6.
183. Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 2002; 30: 746-53.
184. Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 2005; 48: 7535-43.
185. Altmann E, Green J, Tintelnot-Blomley M. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1 substituents. Bioorg Med Chem Lett 2003; 13: 1997-2001.
186. Altmann E, Renaud J, Green J, Farley D, Cutting B, Jahnke W. Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. J Med Chem 2002; 45: 2352-4.
187. Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, et al. Novel and potent cyclic cyanamide-based cathepsin K inhibitors. Bioorg Med Chem Lett 2005; 15: 1815-9.
188. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, et al. Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions. Bioorg Med Chem Lett 2004; 14: 4897-902.
189. Barrett DG, Boncek VM, Catalano JG, Deaton DN, Hassell AM, Jurgensen CH, et al. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett 2005; 15: 3540-6.
190. Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, et al. A structural screening approach to ketoamidebased inhibitors of cathepsin K. Bioorg Med Chem Lett 2005; 15: 2209-13.
191. Barrett DG, Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, et al. Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett 2005; 15: 3039-43.
192. Catalano JG, Deaton DN, Furfine ES, Hassell AM, McFadyen RB, Miller AB, et al. Exploration of the P1 SAR of aldehyde cathepsin K inhibitors. Bioorg Med Chem Lett 2004; 14: 275-8.
193. Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller LR, Payne JA, et al. Design of small molecule ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett 2004; 14: 719-22.
194. Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, et al. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. J Med Chem 2004; 47: 588-99.
195. Tavares FX, Deaton DN, Miller AB, Miller LR, Wright LL, Zhou HQ. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K. J Med Chem 2004; 47: 5049-56.
196. Tavares FX, Deaton DN, Miller LR, Wright LL. Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications. J Med Chem 2004; 47: 5057-68.
197. Tavares FX, Deaton DN, Miller AB, Miller LR, Wright LL. Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles. Bioorg Med Chem Lett 2005; 15: 3891-5.
198. Palmer JT, Bryant C, Wang DX, Davis DE, Setti EL, Rydzewski RM, et al. Design and synthesis of tri-ring P3 benzamidecontaining aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J Med Chem 2005; 48: 7520-34.
199. Palmer JT, Rasnick D, Klaus JL, BrömmeD. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995; 38: 3193-6.
200. Thurmond RL, Sun S, Karlsson L, Edwards JP. Cathepsin S inhibitors as novel immunomodulators. Curr Opin Investig Drugs 2005; 6: 473-82.
201. Thurmond RL, Beavers MP, Cai H, Meduna SP, Gustin DJ, Sun S, et al. Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S. J Med Chem 2004; 47: 4799-801.
202. Thurmond RL, Sun S, Sehon CA, Baker SM, Cai H, Gu Y, et al. Identification of a potent and selective noncovalent cathepsin S inhibitor. J Pharmacol Exp Ther 2004; 308: 268-76.
203. Gustin DJ, Sehon CA, Wei J, Cai H, Meduna SP, Khatuya H, et al. Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors. Bioorg Med Chem Lett 2005; 15: 1687-91.
204. Friedrichs B, Tepel C, Reinheckel T, Deussing J, von Figura K, Herzog V, et al. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest 2003; 111: 1733-45.
205. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, Reinheckel T, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000; 106: 773-81.
206. Wolters PJ, Pham CT, Muilenburg DJ, Ley TJ, Caughey GH. Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem 2001; 276: 18551-6.
207. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005; 118: 1493-503.
208. Mallen-St Clair J, Pham CT, Villalta SA, Caughey GH, Wolters PJ. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 2004; 113: 628-34.
209. Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP, et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006; 113: 98-107.
210. Buhling F, Rocken C, Brasch F, Hartig R, Yasuda Y, Saftig P, et al. Pivotal role of cathepsin K in lung fibrosis. Am J Pathol 2004; 164: 2203-16.
211. Tobin DJ, Foitzik K, Reinheckel T, Mecklenburg L, Botchkarev VA, Peters C, et al. The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am J Pathol 2002; 160: 1807-21.
212. Stypmann J, Glaser K, Roth W, Tobin DJ, Petermann I, Matthias R, et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA 2002; 99: 6234-9.
213. Petermann I, Mayer C, Stypmann J, Biniossek ML, Tobin DJ, Engelen MA, et al. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. FASEB J 2006.
214. Honey K, Nakagawa T, Peters C, Rudensky A. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands. J Exp Med 2002; 195: 1349-58.
215. Yasothornsrikul S, Greenbaum D, Medzihradszky KF, Toneff T, Bundey R, Miller R, et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci USA 2003; 100: 9590-5.
216. Maehr R, Mintern JD, Herman AE, Lennon-Dumenil AM, Mathis D, Benoist C, et al. Cathepsin L is essential for onset of autoimmune diabetes in NOD mice. J Clin Invest 2005; 115: 2934-43.
217. Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003; 111: 897-906.
218. Rodgers KJ, Watkins DJ, Miller AL, Chan PY, Karanam S, Brissette WH, et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006; 26: 851-6.
219. Liu J, Ma L, Yang J, Ren A, Sun Z, Yan G, et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2005.
220. Ondr JK, Pham CT. Characterization of murine cathepsin W and its role in cell-mediated cytotoxicity. J Biol Chem 2004; 279: 27525-33.
221. Buemi M, Aloisi C, Fulvio F, Caccamo C, Cavallaro E, Crasci E, et al. Cardiorenal consequences of atherosclerosis and statins therapy: from the past to the future. Curr Pharm Des 2005; 11(30): 3973-84.
222. Carragher N. O. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Des 2006; 12(5): 615-38.
223. Jones T. B, McDaniel E. E, Popovich P. G. Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des 2005; 11(10): 1223-36.